Search database
Filter
296
Text search: tuberkulose
Featured
Language
Document type
146
50
46
14
13
7
7
6
3
2
1
1
Countries / Regions
75
17
16
6
5
4
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
43
14
13
9
8
6
6
5
5
5
5
4
4
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
Category
104
30
8
3
3
2
2
Toolboxes
143
61
27
24
15
6
6
4
3
2
1
1
1
1
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Version: 24 April 2018
2nd edition. T The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or sympt ... more
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med ... more

Diagnostics Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO
Stop TB`s GDF provides a wide range of diagnostic equipment and laboratory supplies in its Diagnostics Catalog

Medicines Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.

Field Guide for the Management of Drug-Resistant Tuberculosis

A. Piubello The International Union Against Tuberculosis and Lung Disease (2018)
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
2nd edition. The practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide
Guía para países de bajos ingresos. 2 edición
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more
The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci ... more
Очень часто дети это уязвимая под-группа внутри уже уязвимых групп населения. Поэтому необходимо, чтобы политики, гражданское общество и медицинские работники без ... more
Поэтому уже давно возникала мысль о том,что подробный комментарий по вопросам научных знаний и практическогоопыта, лежащих в основе политики ВОЗ по борьбе ... more

Диагностика и лечение туберкулеза с множественной лекарственной устойчивостью возбудителя

Васильева Ирина Анатольевна, Самойлова Анастасия Геннадьевна, Эргешов Атаджан Эргешович et al. федеральное государственное бюджетное учреждение центральный научно-исследовательский институт туберкулеза российской академии медицинских наук, Американский международный союз здравоохранения (2012) C2
Cовершенствование теоретических знаний и практических навыков по вопросам диагностики и лечения туберкулеза с множественной лекарственной устойчивостью (МЛУ) ми ... more
Это руководство предназначено для использования в качестве пособия дл яврачей и других медицинских работников, осуществляющих лечение и уход за больными лекарст ... more
Third edition.
This training toolkit by the European Laboratory Initiative for TB, HIV and Viral Hepatitis provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB).